Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Aug 29 (Reuters) - Esperion Therapeutics Inc ESPR.O:
ESPERION’S BEMPEDOIC ACID RECEIVES LEVEL 1A RECOMMENDATION IN UPDATED ESC/EAS GUIDELINES FOR MANAGEMENT OF DYSLIPIDAEMIAS
ESPERION THERAPEUTICS INC - BEMPEDOIC ACID RECOMMENDED FOR PATIENTS UNABLE TO TAKE STATIN THERAPY TO ACHIEVE LDL-C GOAL. CLASS I, LEVEL B
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Meme Stocks Reappear. Avis Shares Reach New Highs Amid Short Squeeze. Can Retail Investors Still Buy?

Tesla Q1 2026 Earnings Preview: 50,000-Unit Inventory Overhang, Energy Storage Halved, 5 Core Metrics Long-Term Investors Should Really Watch

Bitmine 2030 Stock Price Prediction: Why Did BMNR Stock Price Fall? How High Will It Rise in the Future?

Strike Threat Could Cost 30 Trillion Won, Can Samsung’s Stock Rally Last?

NVDA Stock vs Micron Technology Stock: Why AI Memory Demand Could Outpace Nvidia’s Next Growth Phase

Tradingkey






